IDH2 and glioma: Results suggest that (1) the combination of various CEST metrics may be useful biomarkers for differentiating IDH and 1p/19q status; (2) the comparison between the two models (asymmetry-based and fluid-suppressed) may be an objective biomarker to identify the gliomas with T2/FLAIR mismatch.